Clinical efficacy was assessed by : -The 21-item Hamilton Rating Scale of Depression-(HRSD) (Hamilton, 1967 ). -A global scale of severity of illness with a 5-point scale (very severe, severe, moderate, mild, nil) .
A clinical assessment of efficacy, was performed at the end of the treatment (D42) with a 6-point rating scale (symptoms cleared, marked improvement, moderate improvement, slight improvement, no change, worse).
Clinical safety was studied using : -Sujective somatic complaints, body weight, heart rate, blood pressure (Phase VKorotkoff) both standing and supine, on Day 0, 7, 14, 21, 28, 35 , and 42) -Laboratory tests ; haematology (haemoglobin, haematocrit, full blood count, including while cell differential), fasting blood glucose, blood urea, serum creatinin, serum alkaline phosphatase, and electrocardiogram, performed on DO and at the end of the treatment (D42).
Study Population
During a period of six months, 40 depressive patients meeting the inclusion criteria and exclusion criteria were thus included in two psychiatric centres at Bombay (20 subjects) and Lucknow (20 patients;. The age of the study population ranged between 22 and 65 years. The other demographic data of the study population are listed in 
Statistical analysis
The time course for the antidepressant parameters has been evaluated wilh ihe nonparametric test of Friedman. When time effect was significant this test was completed by a two-wav comparison ol the scores obtained at different moments.
The biological and cardiovascular parameters were compared by a two-way analyses of variance. When a time eflcct was significant the analysis was followed with the Newman-Keuls test.
RESULTS
Seventeen subjects were treated with amineptine alone. In 12 subjects amineptine therapy was com'**iii'*d with hypnotic therapy (llura/epatn : 5: nitrazepam :7), while 15 subjects needed concomitant therapy with anxiolytic therapv ehlordia/e*>o\idc :7; diazepam: •>: lora/.cpatn:2;.
One subject was dialed throughout the studv with propranolol because ol bengin essential tremors.
Seven subjects were withdrawn Iroin the study, five because ol lack of improvement and two others due to poor follow up.
Antidepressant efficacy
The total score ol the Hamilton Rating Scale of Depression improved significantly zo.ooi *Th-time effect is based on the overall results of 6 weeks treatment.
from 22.8 ±0.7 at week 0 to 11.9 ± 1.3 after 6 weeks of treatment (p< 0.001). The improvement became significant after 2 weeks of treatment (17.3 rb 1 ; p<0.05) and progressed further throughout the study (p<0.01). Subanalysis of the evolution of the individual items of this scale showed a significant improvement of 12 items, especially related to severity of depression, quality of sleep and psychomotor activity, anxiety and somatic symptoms (Table III) . No individual item improved significantly within 2 weeks of treatment.
The score of the Clinical Global Evaluation decreased progressively with a significant difference with baseline values after 4 weeks treatment (p<0.01). It suggests a gradual improvement of the average mood state of the subjects.
Overall clinical assessment showed that 21 out of 37 patients improved (56.8%) to a moderate degree or more, 21.6% of patients were reported to have slight improvement whereas 21.6% showed no change or worsening in their conditions (Table IV) .
A subsequent analysis of the Hamilton Rating Scale of Depression and the Clinical Global Evaluation was performed on the moderate to marked responders.
The scores on Hamilton Rating Scale of Depression decreased from 23.4 ± 1.0 to 6.9 ± 1.8 (p<0.001), while the Clinical Global revaluation showed reduction from 2.3±0.1 at the entry of the study to 0.6 ±0.2 at the end.
Safety Parameters
Complaints of patients Amineptine was well tolerated. In total 11 side effects were reported that might be related to amineptine in our opinion. (Table V) . The most frequent reported effect was dryness of the mouth of which three patients complained. One patient developed jaundice after three weeks of treatment, but we could not establish the etiology of this symptom as this patient was lost to follow up. Effect on body weight There was a small but statistically significant increase in body weight from 53.6 x 1.7 Kg at baseline to 53.8 1 1.7 Kg at the end of treatment (p-^0.02;.
Biological parameters
Except for a small but significant increase in average haemoglobin values from 12.27 ± 0.24 to 12.51 :0.26 g/lOOml (p<0.05), no significant clianges occurred in any of the tested biological parameters. A careful examination of individual data revealed no pathological changes in any of the patients that completed the study.
Cardiovascular parameters
No adverse cardiovascular effects were noted. Heart rate reduced significantly during the trial from 92.9.i ; 1.2 at baseline to 79.9±0.6 at the end of treatment (p<0.01). Standing systolic blood pressure decreased significantly from 123.8 f.1.9 to 122.1 L 1.9 mmHg at the end of treatment (p -0.03). The other blood pressure values remained unchanged. The difference between supine and standing blood pressure did not change on amineptine. Case by case analysis of all cardiovascular parameters including E.C.G. recordings did not reveal any abnormality.
DISCUSSION
This open study involved 40 patients with major depressions, bipolar disorders and dysthymic disorders according to DSM III criteria.
From the start of therapy with amineptine the mood level of the included patients showed a positive trend, the antidepressant effect of amineptine reached significance after two weeks therapy in the Hamilton Rating Scale of Depression nrtd after four weeks in the Clinical Global Evaluation. This relatively late onset of action is contradictory to earlier studies with amineptine (Oules and Boscredon, 1983; Kammerer rt al., 1981; Dicker & Wagner, 1981; Dcni Keretal, 1982; Vauterin & Ba/.ot, 1979; Bomstrin, 1979; Lemoine et al., 1981; Van Amctongcn, 1979 and Perot et al., 1980) . It is probably related to the low Marling dosages of amineptine used in the tirst week of treatment during this trial.
None of the individual items of the Hamilton Rating Scale of Depression improved significantly within 2 weeks . of treatment, which suggests that the improvement of the quality of sleep and anxiety is related to the anti-depressant activity of amineptine and unrelated to the concomittant use of hypnotics or anxiolytics.
In general amineptine was well tolerated in this study. The most frequent reported side effect was dryness of the mouth.
Unfortunately, the patient who developed jaundice after three weeks of treatment was lost to follow-up and we were unable to establish the eliology of this symptom. As infectious hepatitis is quite common in India, it is unlikely that this case of jaundice is related to drug therapy. It is well known however that hepatitis may occur during therapy with antidepressant drugs, including amineptine, This side effect normally disappears after discontinuation of therapy (Yon and Anuras, 1975; Moskovitz et al., 1982; Andrieu et al., 1982) .
The small increase in average body weight during this trial may be a secondary result of increased appetite or due to the antidepressant effect of amineptine.
The slight increase in haemoglobin value is of no clinical importance. As no other biological parameter changed, we may conclude that the biological tolerance of amineptine was excellent.
Amineptine caused a small decrease in heart-rate and standing systolic blood pressure, but both changes arc of no clinical importance. All other cardiovascular parameters remained normal.
There was no difference between standing and supine blood pressure levels and thus amineptine caused no postural hypotension. Other tricyclic antidepressants may cause postural hypotension in as many as 20% of patirnts (Glassman et al.. 1979> "
The ECG recordings did not show any ST change, difference in QRS duration or T top inversion which suggests that amineptine has no harmful effect on myocardial function and confirms the results obtained in other studies (Boehnert & Lovejoy, 1985 and Agnoli et al., 1982) .
Amineptine seems to be a useful addition to the existing antidepressant drugs.
